ENV-308
Phase 1 per company
Since , the date of the source that reports this phase.
Summary
ENV-308 is a program from Enveda. The source describes it as small molecule (oral). It is being developed for metabolic health, weight maintenance after GLP-1 treatment. Per the company, it was at Phase 1 as of Dec 17, 2025. The AI role named in the source is molecule design. About the company, based in United States: AI and metabolomics platform that decodes natural chemistry to find new small-molecule medicines; lead ENV-294 is in Phase 2 for atopic dermatitis and asthma. IND in effect, first patient dosed. The latest dated source is from Dec 17, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Enveda
- Indication
- Metabolic health, weight maintenance after GLP-1 treatment
- Therapeutic area
- Other
- Modality
- Small molecule (oral)
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Dec 17, 2025
- Phase source
- X only
- Board column
- Phase 1
- Trial record
- none found on CT.gov or EU CTIS
Key readouts in the source
IND in effect, first patient dosed
AI evidence
AI source: Company
“ENV-308 was discovered using PRISM , Enveda’s proprietary AI model”
Milestone timeline
-
Official X post: Phase 1
IND in effect, first patient dosed
About Enveda
AI and metabolomics platform that decodes natural chemistry to find new small-molecule medicines; lead ENV-294 is in Phase 2 for atopic dermatitis and asthma.
Spot an error? Tell me and I'll fix it.